Filter by Lead Doctor (All Doctors) Przemyslaw Twardowski, M.D.Jennifer Linehan, M.D.Przemyslaw Twardowski, M.D. Title Physician Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study NCT ID : NCT05987241 Phase : 2/3 Location : Saint John's Cancer Institute Przemyslaw Twardowski, M.D. Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer NCT ID : 05803941 Phase : 4 Location : Saint John's Cancer Institute Przemyslaw Twardowski, M.D. Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician’s Choice New Hormonal Agents (EvoPAR-PR01) NCT ID : 06120491 Phase : 3 Location : Saint John's Cancer Institute Przemyslaw Twardowski, M.D. A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer NCT ID : 05483868 Phase : 1 Location : Saint John's Cancer Institute Jennifer Linehan, M.D. Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer (Solar-Recur) NCT ID : 06235151 Phase : 3 Location : Saint John's Cancer Institute Przemyslaw Twardowski, M.D. Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer NCT ID : 03972657 Protocol Number : R5678-ONC-1879 Phase : 1/2 Location : Saint John's Cancer Institute Przemyslaw Twardowski, M.D.
